Experimental HIV vaccine enters human testing – could it train the body to fight the virus?
NCT ID NCT06796686
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 trial tests a two-part HIV vaccine regimen in 42 healthy adults without HIV. The first shot primes the immune system, and later booster shots aim to mature antibody-producing cells. The main goal is to see if the regimen is safe and whether it triggers a specific immune response that could lead to broadly neutralizing antibodies against HIV.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HIV vaccine (426c.Mod.Core-C4b and HxB2.WT.Core-C4b with adjuvants 3M-052 AF and alum)
What this could lead to
If successful, this could point toward a vaccine that trains the immune system to make broadly neutralizing antibodies against HIV.
What could go wrong
This is a very early Phase 1 trial with only 42 healthy people. It primarily checks safety, not effectiveness. The vaccine may not produce the desired immune response or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bridge HIV, San Francisco Department of Public Health
NOT_YET_RECRUITINGSan Francisco, California, 94102, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Columbia Physicians & Surgeons
NOT_YET_RECRUITINGNew York, New York, 10032, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NY Blood Center CRS
WITHDRAWNNew York, New York, 10065, United States
-
Ponce de Leon Center CRS
NOT_YET_RECRUITINGAtlanta, Georgia, 30308, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Hope Clinic of the Emory Vaccine Research Center; Emory University
RECRUITINGDecatur, Georgia, 30030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••